itory (possibly synergistic) effect on NF-κB activity ( fig. 1 ) , and (b) opposite effects on the NF-κB pathway of current smoking (stimulatory effect via a prooxidant effect) [5] and Se (inhibitory effect via an antioxidant action) [9] ( fig. 1 ). Therefore, a detailed analysis of the influence of smoking upon any antioxidant therapy in patients with GO would be valuable.
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Dear Sir, Increased generation of reactive oxygen species (ROS) is thought to play a role in the pathogenesis of Graves' ophthalmopathy (GO) [1, 2] . Selenium (Se) is an antioxidant agent that has been recently shown to improve significantly the course of mild GO [2] . There is good evidence that oxidative stress plays a role in GO: orbital fibroblasts of GO patients have higher contents of malondialdehyde, superoxide anions and hydrogen peroxide than control orbital fibroblasts [3] . Orbital fibroblasts are recognized as the prime target cells of the autoimmune attack in GO [3] .
We suggest a possible interplay between nuclear factor-κB (NF-κB), pro-inflammatory cytokines (which activate and are activated by NF-κB, by amplifying and perpetuating orbital inflammation), ROS, Se and glucocorticoids (GC) ( fig. 1 ) in GO [4, 5] . Many of the GC effects are mediated through an inhibition of NF-κB [6] ( fig. 1 ) . GC binding to its receptor may have a dual effect on gene activation such as activation of transcription (transactivation) or a suppression of transcription (transrepression) by interacting with NF-κB; consequently, the production of anti-inflammatory proteins is increased (transactivation), whereas the inflammatory ones are diminished (transrepression) [7] .
In our view, the decreased efficacy of GC therapy in current smokers [8] might be explained -at least in part -by the antagonism GC -ROS revealed at the NF-κB level [4] ( fig. 1 ) . Cigarette smoking is a major source of ROS which are able to stimulate the NF-κB pathway ( fig. 1 ), a cornerstone of immune and inflammatory response [5] .
Future studies (immunosuppressive therapy plus Se) in patients with more severe GO are, at least in part, justified by the following data: (a) GC [6, 7] and Se [9] seem to have a similar inhib- 
